Journey Medical Corporation (DERM)

NASDAQ: DERM · IEX Real-Time Price · USD
2.61
0.00 (0.00%)
Sep 28, 2022 4:30 PM EDT - Market closed
0.00%
Market Cap 45.93M
Revenue (ttm) 78.71M
Net Income (ttm) -41.30M
Shares Out 17.60M
EPS (ttm) -3.73
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,799
Open 2.61
Previous Close 2.61
Day's Range 2.53 - 2.73
52-Week Range 2.47 - 10.20
Beta n/a
Analysts Buy
Price Target 9.18 (+251.7%)
Earnings Date Jun 22, 2022

About DERM

Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant acne; Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; Ximino, an oral minocycline drug for the treatment of moderate to severe acne; and Exelderm cream and... [Read more...]

Industry Drug Manufacturers-Specialty & Generic
IPO Date Nov 12, 2021
Employees 90
Stock Exchange NASDAQ
Ticker Symbol DERM
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 9 analysts, the average rating for DERM stock is "Buy." The 12-month stock price forecast is 9.18, which is an increase of 251.72% from the latest price.

Price Target
$9.18
(251.72% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Journey Medical Corporation Announces 50% Enrollment Milestone Achieved in Phase 3 Clinical Trials Evaluating DFD-29 ...

Topline data expected in the first half of 2023 Topline data expected in the first half of 2023

Other symbols: FBIO
4 weeks ago - GlobeNewsWire

Journey Medical Corporation (DERM) Reports Q2 Loss, Lags Revenue Estimates

Journey Medical Corporation (DERM) delivered earnings and revenue surprises of -72% and 13.97%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

Journey Medical Corporation Reports Second Quarter 2022 Financial Results and Recent Corporate Highlights

Second quarter 2022 net revenue increased 20% to $18.3 million versus the same quarter of 2021

Other symbols: FBIO
1 month ago - GlobeNewsWire

Journey Medical Corporation Announces Settlement Agreements Pertaining to QBREXZA®, AMZEEQ® and ZILXI® Patent Exclusi...

SCOTTSDALE, Ariz., May 24, 2022 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ: DERM) (“Journey Medical” or the “Company”), a commercial-stage pharmaceutical company that focuses on the develop...

4 months ago - GlobeNewsWire

Journey Medical Corporation to Present at the B. Riley Securities 22nd Annual Institutional Investor Conference

SCOTTSDALE, Ariz., May 23, 2022 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical”) (NADSAQ: DERM), a commercial-stage pharmaceutical company that focuses on the development and commerci...

4 months ago - GlobeNewsWire

Journey Medical Corporation Reports First Quarter 2022 Financial Results and Recent Corporate Highlights

Generated record revenue of $23.3 million for the first quarter of 2022

Other symbols: FBIO
4 months ago - GlobeNewsWire

Journey Medical Corporation to Announce First Quarter 2022 Financial Results on May 10, 2022

Company to host conference call to discuss financial results and provide a corporate update on May 10, 2022 at 4:30 p.m. ET Company to host conference call to discuss financial results and provide a cor...

Other symbols: FBIO
4 months ago - GlobeNewsWire

Journey Medical Corporation (DERM) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

After losing some value lately, a hammer chart pattern has been formed for Journey Medical Corporation (DERM), indicating that the stock has found support. This, combined with an upward trend in earning...

5 months ago - Zacks Investment Research

Journey Medical Corporation to Present at the Virtual Fortress Biotech R&D Summit Hosted by B. Riley Securities

SCOTTSDALE, Ariz., April 04, 2022 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical”) (NADSAQ: DERM), a commercial-stage pharmaceutical company that focuses on the development and commer...

5 months ago - GlobeNewsWire

Journey Medical Corporation Reports Full-Year 2021 Financial Results and Recent Corporate Highlights

Generated record net product revenues of $63.1 million for the full year 2021

Other symbols: FBIO
6 months ago - GlobeNewsWire

Journey Medical Corporation to Release Year End 2021 Financial Results and Provide Corporate Update on March 23, 2022

Company to hold conference call on March 23, 2022 at 4:30 p.m. ET Company to hold conference call on March 23, 2022 at 4:30 p.m. ET

6 months ago - GlobeNewsWire

Journey Medical Corporation Announces First Patient Dosed in Phase 3 Clinical Trial Evaluating DFD-29 (Minocycline Mo...

Published Phase 2 clinical data show DFD-29 had approximately double the efficacy compared to Doxycycline capsules 40 mg on reducing total inflammatory lesions and IGA treatment success Published Phase ...

6 months ago - GlobeNewsWire

QBREXZA® (Rapifort® Wipes 2.5%) Receives Manufacturing and Marketing Approval in Japan Triggering $2.5 Million Milest...

SCOTTSDALE, Ariz., Feb. 11, 2022 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ: DERM) (“Journey Medical”), a commercial-stage pharmaceutical company that focuses on the development and commerc...

7 months ago - GlobeNewsWire

Journey Medical Corporation Acquires Two FDA-Approved Topical Minocycline Products and Molecule Stabilizing Technolog...

Franchise includes AMZEEQ® for the treatment of acne and ZILXI® for the treatment of rosacea, and a development-stage dermatology program (FCD105) along with the MST proprietary platform

8 months ago - GlobeNewsWire

Journey Medical Corporation Reports Third Quarter 2021 Financial Results and Recent Corporate Highlights

Generated record net revenues of $19.6 million for the third quarter of 2021

9 months ago - GlobeNewsWire

Journey Medical Corporation Announces Closing of Initial Public Offering

SCOTTSDALE, Ariz., Nov. 16, 2021 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ: DERM) (“Journey Medical”), a commercial-stage pharmaceutical company that focuses on the development and commerc...

Other symbols: FBIO
10 months ago - GlobeNewsWire

All the 2020 Pre-JPM News Healthcare Investors Need to Know

The Super Bowl of healthcare kicked off early for these companies.

2 years ago - The Motley Fool

Eli Lilly Reports Deal To Buy Dermira For $1.1B

Eli Lilly (NYSE: LLY) announced Friday it will acquire Dermira, Inc. (NASDAQ: DERM) for $18.75 per share, around $1.1 billion, in an all-cash transaction.

Other symbols: LLY
2 years ago - Benzinga

Eli Lilly to buy Dermira in a deal valued at $1.1 billion

Eli Lilly & Co. LLY, +1.65% announced Friday a deal to buy medical dermatology company Dermira Inc.

Other symbols: LLY
2 years ago - Market Watch

Buy Multibagger Stocks as Odds of a Rally Are High in 2020

Multibagger stocks can make most of the bull run, courtesy of strong fundamentals and businesses that can multiply in a short span of time.

Other symbols: AGRXAIRIMBOTSAVA
2 years ago - Zacks Investment Research

Moving Average Crossover Alert: Dermira

Dermira, Inc. (DERM) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.

2 years ago - Zacks Investment Research

Will Dermira Continue to Surge Higher?

As of late, it has definitely been a great time to be an investor in Dermira.

2 years ago - Zacks Investment Research

4 More Biotechs With Blockbuster Potential

On Dec. 17, GuruFocus reported that in a July article, Kiplinger identified Morphic Holding Inc.

Other symbols: AKROGBTMRNA
2 years ago - GuruFocus

Here's Why Dermira Stock Popped Today

Investors are thrilled with the FDA's decision to grant its eczema drug a speedy review.

2 years ago - The Motley Fool

Here's Why Dermira Stock Is Soaring Today

The demise of a potential competitor gave Dermira investors a reason to cheer.

2 years ago - The Motley Fool